{"id":7110,"date":"2025-04-09T14:58:39","date_gmt":"2025-04-09T14:58:39","guid":{"rendered":"https:\/\/beonemedicines.ca\/?page_id=7110"},"modified":"2025-11-05T17:40:57","modified_gmt":"2025-11-05T17:40:57","slug":"research-and-development","status":"publish","type":"page","link":"https:\/\/beonemedicines.ca\/en\/science\/research-and-development\/","title":{"rendered":"Research & Development"},"content":{"rendered":"\r\n
\r\n
\r\n \"Watermark\"\r\n <\/div>\r\n
\r\n
\r\n
\r\n
\r\n \"Watermark\"\r\n <\/div>\r\n
\r\n
\r\n \r\n

Research & Development<\/h1>\r\n <\/div>\r\n
\r\n

We have built a groundbreaking, global cancer research and development model that is designed to deliver breakthroughs for some of the world\u2019s most challenging cancers.<\/p>\n<\/div>\r\n \r\n <\/div>\r\n\r\n \r\n \r\n \r\n <\/div>\r\n <\/div>\r\n\r\n

\r\n
\r\n \"Scientist\r\n <\/div>\r\n <\/div>\r\n \t\t\t\t\t\r\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n \r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
Our Approach\u202fto Cancer Research<\/h6> \r\n \r\n

Innovation that Leads with Science and Leverages Scale<\/h2>\r\n <\/div>\r\n

At BeOne Medicines, we are purpose-built to accelerate the development and delivery of innovative medicines to address some of the greatest unmet needs in cancer.<\/p>\n

Our team of dedicated scientists in biology, chemistry, pharmacology, translational medicine and clinical science has a deep and nuanced understanding of cancer. They apply their diverse expertise to explore a vast selection of preclinical candidates and generate proof-of-concept data that enables us to accelerate the most promising compounds into clinical trials. This approach strengthens our ability to deliver a higher volume of potentially transformative medicines possibly as, first-or-best-in-class.<\/p>\n

We also manage our extensive clinical research program in-house, which creates efficiencies in scale that allow for optimum decision-making and program delivery.<\/p>\n

As we innovate with urgency, we follow a rigorous, science-forward approach to develop novel investigational medicines that:<\/p>\n<\/div>\r\n \r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n

\r\n
\r\n
\r\n
\r\n
\r\n \"Icon\r\n <\/div>\t\r\n \r\n
\r\n

Disrupt key drivers of cell growth and survival <\/h4>\r\n <\/div>\t\t\t\t\t\t\t\t\r\n <\/div>\r\n \r\n \r\n <\/div>\r\n <\/div>\r\n
\r\n
\r\n
\r\n
\r\n \"Icon\r\n <\/div>\t\r\n \r\n
\r\n

Harness the body\u2019s immune system to attack tumors<\/h4>\r\n <\/div>\t\t\t\t\t\t\t\t\r\n <\/div>\r\n \r\n \r\n <\/div>\r\n <\/div>\r\n
\r\n
\r\n
\r\n
\r\n \"Icon\r\n <\/div>\t\r\n \r\n
\r\n

Target specific cancer biomarkers<\/h4>\r\n <\/div>\t\t\t\t\t\t\t\t\r\n <\/div>\r\n \r\n \r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n<\/section>\r\n\n\n\r\n
\r\n
\r\n
\r\n \r\n
\r\n \r\n
\r\n
\r\n \r\n
\r\n
\r\n
Our Expansive Pipeline<\/h6>\r\n

Developing the Medicines of Tomorrow<\/h2>\r\n <\/div>\r\n
\r\n \r\n

Our team innovates with intent. Our research and development model is built to drive decisive, clinically informed action at every stage of development. We are committed to delivering medicines that tackle the most pressing needs of patients\u2014today and into the future.<\/p>\n

Comprised of more than 40 clinical and commercial assets, our pipeline is designed to address a wide range of hematologic and solid tumor cancers. We are exploring many different modalities alone and in combination, including small molecules, protein degraders, bi\/multi-specific antibodies, monoclonal antibodies, antibody drug conjugates and cytokine therapy.<\/p>\n

We actively look for ways to involve patients and caregivers in our research and development process. Their insights help us design clinical trials that are more practical and patient-friendly, leading to faster enrollment and better representation of people from around the world.<\/p>\n<\/div>\r\n <\/div>\r\n \r\n \r\n